Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Mitotane
- Accession Number
- DB00648 (APRD00494)
- Type
- Small Molecule
- Groups
- Approved
- Description
A derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. [PubChem]
- Structure
Structure for DB00648 (Mitotane)
- Synonyms
- Mitotan
- Mitotane
- Mitotano
- Mitotanum
- Piprine-DDD, O-
- External IDs
- CB 313 / NSC 38721
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Lysodren Tablet 500 mg Oral Bristol Myers Squibb 1979-12-31 Not applicable Canada 
Lysodren Tablet 500 mg/1 Oral E.R. Squibb & Sons, L.L.C. 2009-06-01 Not applicable US 
Lysodren Tablet 500 mg Oral Laboratoire HRA Pharma 2004-04-28 Not applicable EU 
- International/Other Brands
- Lisodren (Bristol-Myers Squibb) / Lysodren / Opeprim (Yakult Honsha)
- Categories
- UNII
- 78E4J5IB5J
- CAS number
- 53-19-0
- Weight
- Average: 320.041
Monoisotopic: 317.953661148 - Chemical Formula
- C14H10Cl4
- InChI Key
- JWBOIMRXGHLCPP-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
- IUPAC Name
- 1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene
- SMILES
- ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
Pharmacology
- Indication
For treatment of inoperable adrenocortical tumours; Cushing's syndrome
- Structured Indications
- Pharmacodynamics
Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotane alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol.
- Mechanism of action
Its biochemical mechanism of action is unknown, although data are available to suggest that the drug modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex.
Target Actions Organism ACytochrome P450 11B1, mitochondrial inducerHuman UAdrenodoxin, mitochondrial unknownHuman UEstrogen receptor alpha Not Available Human UProgesterone receptor Not Available Human UAndrogen receptor antagonistHuman - Absorption
About 40% oral Lysodren is absorbed
- Volume of distribution
- Not Available
- Protein binding
6%
- Metabolism
Hepatic and renal
- Route of elimination
A variable amount of metabolite (1%-17%) is excreted in the bile and the balance is apparently stored in the tissues.
- Half life
18-159 days
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Mitotane. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane. Experimental, Illicit 5-androstenedione The serum concentration of 5-androstenedione can be decreased when it is combined with Mitotane. Experimental, Illicit Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with Mitotane. Approved, Investigational Abiraterone The serum concentration of Abiraterone can be decreased when it is combined with Mitotane. Approved Acenocoumarol The serum concentration of Acenocoumarol can be decreased when it is combined with Mitotane. Approved, Investigational Acetaminophen The serum concentration of Acetaminophen can be decreased when it is combined with Mitotane. Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Mitotane. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Mitotane. Experimental Adinazolam The serum concentration of Adinazolam can be decreased when it is combined with Mitotane. Approved Albendazole The serum concentration of Albendazole can be decreased when it is combined with Mitotane. Approved, Vet Approved Alclometasone The serum concentration of Alclometasone can be decreased when it is combined with Mitotane. Approved Aldosterone The serum concentration of Aldosterone can be decreased when it is combined with Mitotane. Experimental, Investigational Alfentanil The serum concentration of Alfentanil can be decreased when it is combined with Mitotane. Approved, Illicit Alfuzosin The serum concentration of Alfuzosin can be decreased when it is combined with Mitotane. Approved, Investigational Aliskiren The serum concentration of Aliskiren can be decreased when it is combined with Mitotane. Approved, Investigational Allylestrenol The serum concentration of Allylestrenol can be decreased when it is combined with Mitotane. Approved Almotriptan The serum concentration of Almotriptan can be decreased when it is combined with Mitotane. Approved, Investigational Alogliptin The serum concentration of Alogliptin can be decreased when it is combined with Mitotane. Approved Alosetron The serum concentration of Alosetron can be decreased when it is combined with Mitotane. Approved, Withdrawn alpha-Tocopherol acetate The serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Mitotane. Approved Alprazolam The serum concentration of Alprazolam can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational Ambrisentan The serum concentration of Ambrisentan can be decreased when it is combined with Mitotane. Approved, Investigational Ambroxol The serum concentration of Ambroxol can be decreased when it is combined with Mitotane. Approved, Investigational Amcinonide The serum concentration of Amcinonide can be decreased when it is combined with Mitotane. Approved Aminophenazone The serum concentration of Aminophenazone can be decreased when it is combined with Mitotane. Approved, Withdrawn Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Mitotane. Approved Amiodarone The serum concentration of Amiodarone can be decreased when it is combined with Mitotane. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be decreased when it is combined with Mitotane. Approved Amlodipine The serum concentration of Amlodipine can be decreased when it is combined with Mitotane. Approved Amprenavir The serum concentration of Amprenavir can be decreased when it is combined with Mitotane. Approved, Investigational Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Mitotane. Approved, Investigational, Withdrawn Androstenedione The serum concentration of Androstenedione can be decreased when it is combined with Mitotane. Experimental, Illicit Anecortave The serum concentration of Anecortave can be decreased when it is combined with Mitotane. Investigational anecortave acetate The serum concentration of anecortave acetate can be decreased when it is combined with Mitotane. Investigational Antipyrine The serum concentration of Antipyrine can be decreased when it is combined with Mitotane. Approved, Investigational Apalutamide The serum concentration of Apalutamide can be decreased when it is combined with Mitotane. Approved, Investigational Apixaban The serum concentration of Apixaban can be decreased when it is combined with Mitotane. Approved Apremilast The serum concentration of Apremilast can be decreased when it is combined with Mitotane. Approved, Investigational Aprepitant The serum concentration of Aprepitant can be decreased when it is combined with Mitotane. Approved, Investigational Argatroban The serum concentration of Argatroban can be decreased when it is combined with Mitotane. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be decreased when it is combined with Mitotane. Approved, Investigational Artemether The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Mitotane resulting in a loss in efficacy. Approved Artemether The serum concentration of Artemether can be decreased when it is combined with Mitotane. Approved Asenapine The serum concentration of Asenapine can be decreased when it is combined with Mitotane. Approved Astemizole The serum concentration of Astemizole can be decreased when it is combined with Mitotane. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Atamestane The serum concentration of Atamestane can be decreased when it is combined with Mitotane. Investigational Atazanavir The serum concentration of Atazanavir can be decreased when it is combined with Mitotane. Approved, Investigational Atorvastatin The serum concentration of Atorvastatin can be decreased when it is combined with Mitotane. Approved Avanafil The serum concentration of Avanafil can be decreased when it is combined with Mitotane. Approved Axitinib The serum concentration of Axitinib can be decreased when it is combined with Mitotane. Approved, Investigational Azelastine The serum concentration of Azelastine can be decreased when it is combined with Mitotane. Approved Azithromycin The serum concentration of Azithromycin can be decreased when it is combined with Mitotane. Approved Banoxantrone The serum concentration of Banoxantrone can be decreased when it is combined with Mitotane. Investigational Baricitinib The serum concentration of Baricitinib can be decreased when it is combined with Mitotane. Approved, Investigational Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Mitotane. Approved, Investigational Bedaquiline The serum concentration of Bedaquiline can be decreased when it is combined with Mitotane. Approved Benidipine The serum concentration of Benidipine can be decreased when it is combined with Mitotane. Approved, Investigational Benzphetamine The serum concentration of Benzphetamine can be decreased when it is combined with Mitotane. Approved, Illicit Benzyl alcohol The serum concentration of Benzyl alcohol can be decreased when it is combined with Mitotane. Approved Betamethasone The serum concentration of Betamethasone can be decreased when it is combined with Mitotane. Approved, Vet Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Mitotane. Approved, Investigational Bexarotene The serum concentration of Bexarotene can be decreased when it is combined with Mitotane. Approved, Investigational Bezafibrate The serum concentration of Bezafibrate can be decreased when it is combined with Mitotane. Approved, Investigational Bicalutamide The serum concentration of Bicalutamide can be decreased when it is combined with Mitotane. Approved Bictegravir The serum concentration of Bictegravir can be decreased when it is combined with Mitotane. Approved, Investigational Bisoprolol The serum concentration of Bisoprolol can be decreased when it is combined with Mitotane. Approved Blonanserin The serum concentration of Blonanserin can be decreased when it is combined with Mitotane. Approved, Investigational Boceprevir The serum concentration of Boceprevir can be decreased when it is combined with Mitotane. Approved, Withdrawn Bortezomib The serum concentration of Bortezomib can be decreased when it is combined with Mitotane. Approved, Investigational Bosentan The serum concentration of Bosentan can be decreased when it is combined with Mitotane. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be decreased when it is combined with Mitotane. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitotane. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be decreased when it is combined with Mitotane. Approved, Investigational Brigatinib The serum concentration of Brigatinib can be decreased when it is combined with Mitotane. Approved, Investigational Brinzolamide The serum concentration of Brinzolamide can be decreased when it is combined with Mitotane. Approved Brivaracetam The serum concentration of Brivaracetam can be decreased when it is combined with Mitotane. Approved, Investigational Bromazepam The serum concentration of Bromazepam can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational Bromocriptine The serum concentration of Bromocriptine can be decreased when it is combined with Mitotane. Approved, Investigational Brompheniramine The serum concentration of Brompheniramine can be decreased when it is combined with Mitotane. Approved Budesonide The serum concentration of Budesonide can be decreased when it is combined with Mitotane. Approved Bupivacaine The serum concentration of Bupivacaine can be decreased when it is combined with Mitotane. Approved, Investigational Buprenorphine The serum concentration of Buprenorphine can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational, Vet Approved Bupropion The serum concentration of Bupropion can be decreased when it is combined with Mitotane. Approved Buspirone The serum concentration of Buspirone can be decreased when it is combined with Mitotane. Approved, Investigational Busulfan The serum concentration of Busulfan can be decreased when it is combined with Mitotane. Approved, Investigational Cabazitaxel The serum concentration of Cabazitaxel can be decreased when it is combined with Mitotane. Approved Cabergoline The serum concentration of Cabergoline can be decreased when it is combined with Mitotane. Approved Cabozantinib The serum concentration of Cabozantinib can be decreased when it is combined with Mitotane. Approved, Investigational Caffeine The serum concentration of Caffeine can be decreased when it is combined with Mitotane. Approved Calcitriol The serum concentration of Calcitriol can be decreased when it is combined with Mitotane. Approved, Nutraceutical Canagliflozin The serum concentration of Canagliflozin can be decreased when it is combined with Mitotane. Approved Cannabidiol The serum concentration of Cannabidiol can be decreased when it is combined with Mitotane. Approved, Investigational Carbamazepine The serum concentration of Carbamazepine can be decreased when it is combined with Mitotane. Approved, Investigational Carbinoxamine The serum concentration of Carbinoxamine can be decreased when it is combined with Mitotane. Approved Cariprazine The serum concentration of Cariprazine can be decreased when it is combined with Mitotane. Approved, Investigational Carvedilol The serum concentration of Carvedilol can be decreased when it is combined with Mitotane. Approved, Investigational Celecoxib The serum concentration of Celecoxib can be decreased when it is combined with Mitotane. Approved, Investigational Celiprolol The serum concentration of Celiprolol can be decreased when it is combined with Mitotane. Approved, Investigational Cephalexin The serum concentration of Cephalexin can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Ceritinib can be decreased when it is combined with Mitotane. Approved Cerivastatin The serum concentration of Cerivastatin can be decreased when it is combined with Mitotane. Approved, Withdrawn Cevimeline The serum concentration of Cevimeline can be decreased when it is combined with Mitotane. Approved Chenodeoxycholic acid The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Mitotane. Approved Chlordiazepoxide The serum concentration of Chlordiazepoxide can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational Chloroquine The serum concentration of Chloroquine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Chlorphenamine The serum concentration of Chlorphenamine can be decreased when it is combined with Mitotane. Approved Chlorpromazine The serum concentration of Chlorpromazine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Chlorzoxazone The serum concentration of Chlorzoxazone can be decreased when it is combined with Mitotane. Approved Cholecalciferol The serum concentration of Cholecalciferol can be decreased when it is combined with Mitotane. Approved, Nutraceutical Ciclesonide The serum concentration of Ciclesonide can be decreased when it is combined with Mitotane. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be decreased when it is combined with Mitotane. Approved, Investigational Cinacalcet The serum concentration of Cinacalcet can be decreased when it is combined with Mitotane. Approved Cisapride The serum concentration of Cisapride can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Citalopram The serum concentration of Citalopram can be decreased when it is combined with Mitotane. Approved Clarithromycin The serum concentration of Clarithromycin can be decreased when it is combined with Mitotane. Approved Clindamycin The serum concentration of Clindamycin can be decreased when it is combined with Mitotane. Approved, Vet Approved Clobazam The serum concentration of Clobazam can be decreased when it is combined with Mitotane. Approved, Illicit Clobetasol The serum concentration of Clobetasol can be decreased when it is combined with Mitotane. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be decreased when it is combined with Mitotane. Approved Clobetasone The serum concentration of Clobetasone can be decreased when it is combined with Mitotane. Approved Clocortolone The serum concentration of Clocortolone can be decreased when it is combined with Mitotane. Approved Clofazimine The serum concentration of Clofazimine can be decreased when it is combined with Mitotane. Approved, Investigational Clofibrate The serum concentration of Clofibrate can be decreased when it is combined with Mitotane. Approved, Investigational clomethiazole The serum concentration of clomethiazole can be decreased when it is combined with Mitotane. Investigational Clomipramine The serum concentration of Clomipramine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Clonazepam The serum concentration of Clonazepam can be decreased when it is combined with Mitotane. Approved, Illicit Clonidine The serum concentration of Clonidine can be decreased when it is combined with Mitotane. Approved Clopidogrel The serum concentration of Clopidogrel can be decreased when it is combined with Mitotane. Approved Clorazepate The serum concentration of Clorazepate can be decreased when it is combined with Mitotane. Approved, Illicit Clotiazepam The serum concentration of Clotiazepam can be decreased when it is combined with Mitotane. Approved, Illicit Clozapine The serum concentration of Clozapine can be decreased when it is combined with Mitotane. Approved Cobimetinib The serum concentration of Cobimetinib can be decreased when it is combined with Mitotane. Approved, Investigational Cocaine The serum concentration of Cocaine can be decreased when it is combined with Mitotane. Approved, Illicit Codeine The serum concentration of Codeine can be decreased when it is combined with Mitotane. Approved, Illicit Colchicine The serum concentration of Colchicine can be decreased when it is combined with Mitotane. Approved Conivaptan The serum concentration of Conivaptan can be decreased when it is combined with Mitotane. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be decreased when it is combined with Mitotane. Approved Copanlisib The serum concentration of Copanlisib can be decreased when it is combined with Mitotane. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be decreased when it is combined with Mitotane. Investigational Corticosterone The serum concentration of Corticosterone can be decreased when it is combined with Mitotane. Experimental Cortisone acetate The serum concentration of Cortisone acetate can be decreased when it is combined with Mitotane. Approved, Investigational Crizotinib The serum concentration of Crizotinib can be decreased when it is combined with Mitotane. Approved Cyclobenzaprine The serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane. Approved Cyclophosphamide The serum concentration of Cyclophosphamide can be decreased when it is combined with Mitotane. Approved, Investigational Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Mitotane. Experimental Cytarabine The serum concentration of Cytarabine can be decreased when it is combined with Mitotane. Approved, Investigational Dabrafenib The serum concentration of Dabrafenib can be decreased when it is combined with Mitotane. Approved, Investigational Daclatasvir The serum concentration of Daclatasvir can be decreased when it is combined with Mitotane. Approved, Investigational Dantrolene The serum concentration of Dantrolene can be decreased when it is combined with Mitotane. Approved, Investigational Dapagliflozin The serum concentration of Dapagliflozin can be decreased when it is combined with Mitotane. Approved Dapsone The serum concentration of Dapsone can be decreased when it is combined with Mitotane. Approved, Investigational Darifenacin The serum concentration of Darifenacin can be decreased when it is combined with Mitotane. Approved, Investigational Darunavir The serum concentration of Darunavir can be decreased when it is combined with Mitotane. Approved Dasabuvir The serum concentration of Dasabuvir can be decreased when it is combined with Mitotane. Approved Dasatinib The serum concentration of Dasatinib can be decreased when it is combined with Mitotane. Approved, Investigational Daunorubicin The serum concentration of Daunorubicin can be decreased when it is combined with Mitotane. Approved Deflazacort The serum concentration of Deflazacort can be decreased when it is combined with Mitotane. Approved, Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Mitotane. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Mitotane. Approved Desonide The serum concentration of Desonide can be decreased when it is combined with Mitotane. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be decreased when it is combined with Mitotane. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Mitotane. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Mitotane. Experimental, Vet Approved Desvenlafaxine The serum concentration of Desvenlafaxine can be decreased when it is combined with Mitotane. Approved, Investigational Deutetrabenazine The serum concentration of Deutetrabenazine can be decreased when it is combined with Mitotane. Approved, Investigational Dexamethasone The serum concentration of Dexamethasone can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Mitotane. Vet Approved Dexchlorpheniramine maleate The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Mitotane. Approved Dexlansoprazole The serum concentration of Dexlansoprazole can be decreased when it is combined with Mitotane. Approved, Investigational Dextromethorphan The serum concentration of Dextromethorphan can be decreased when it is combined with Mitotane. Approved Dextropropoxyphene The serum concentration of Dextropropoxyphene can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational, Withdrawn Diazepam The serum concentration of Diazepam can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational, Vet Approved Diclofenac The serum concentration of Diclofenac can be decreased when it is combined with Mitotane. Approved, Vet Approved Dienogest The serum concentration of Dienogest can be decreased when it is combined with Mitotane. Approved Diflorasone The serum concentration of Diflorasone can be decreased when it is combined with Mitotane. Approved Difluocortolone The serum concentration of Difluocortolone can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be decreased when it is combined with Mitotane. Approved Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Mitotane. Approved, Investigational Digoxin The serum concentration of Digoxin can be decreased when it is combined with Mitotane. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitotane. Approved Dihydrocodeine The serum concentration of Dihydrocodeine can be decreased when it is combined with Mitotane. Approved, Illicit Dihydroergotamine The serum concentration of Dihydroergotamine can be decreased when it is combined with Mitotane. Approved, Investigational Diltiazem The serum concentration of Diltiazem can be decreased when it is combined with Mitotane. Approved, Investigational Disopyramide The serum concentration of Disopyramide can be decreased when it is combined with Mitotane. Approved Disulfiram The serum concentration of Disulfiram can be decreased when it is combined with Mitotane. Approved Docetaxel The serum concentration of Docetaxel can be decreased when it is combined with Mitotane. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be decreased when it is combined with Mitotane. Approved, Investigational Dolasetron The serum concentration of Dolasetron can be decreased when it is combined with Mitotane. Approved, Investigational Domperidone The serum concentration of Domperidone can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Donepezil The serum concentration of Donepezil can be decreased when it is combined with Mitotane. Approved Dorzolamide The serum concentration of Dorzolamide can be decreased when it is combined with Mitotane. Approved Doxepin The serum concentration of Doxepin can be decreased when it is combined with Mitotane. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be decreased when it is combined with Mitotane. Approved, Investigational Dronabinol The serum concentration of Dronabinol can be decreased when it is combined with Mitotane. Approved, Illicit Dronedarone The serum concentration of Dronedarone can be decreased when it is combined with Mitotane. Approved Dutasteride The serum concentration of Dutasteride can be decreased when it is combined with Mitotane. Approved, Investigational Efavirenz The serum concentration of Efavirenz can be decreased when it is combined with Mitotane. Approved, Investigational Elbasvir The serum concentration of Elbasvir can be decreased when it is combined with Mitotane. Approved Eletriptan The serum concentration of Eletriptan can be decreased when it is combined with Mitotane. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be decreased when it is combined with Mitotane. Approved Elvitegravir The serum concentration of Elvitegravir can be decreased when it is combined with Mitotane. Approved Enalapril The serum concentration of Enalapril can be decreased when it is combined with Mitotane. Approved, Vet Approved Enasidenib The serum concentration of Enasidenib can be decreased when it is combined with Mitotane. Approved, Investigational Enzalutamide The serum concentration of Enzalutamide can be decreased when it is combined with Mitotane. Approved Epinastine The serum concentration of Epinastine can be decreased when it is combined with Mitotane. Approved, Investigational Eplerenone The serum concentration of Eplerenone can be decreased when it is combined with Mitotane. Approved Equilenin The serum concentration of Equilenin can be decreased when it is combined with Mitotane. Experimental Equilin The serum concentration of Equilin can be decreased when it is combined with Mitotane. Approved Ergocalciferol The serum concentration of Ergocalciferol can be decreased when it is combined with Mitotane. Approved, Nutraceutical Ergoloid mesylate The serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane. Approved Ergonovine The serum concentration of Ergonovine can be decreased when it is combined with Mitotane. Approved Ergotamine The serum concentration of Ergotamine can be decreased when it is combined with Mitotane. Approved Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Mitotane. Approved, Investigational Erythromycin The serum concentration of Erythromycin can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Escitalopram The serum concentration of Escitalopram can be decreased when it is combined with Mitotane. Approved, Investigational Esomeprazole The serum concentration of Esomeprazole can be decreased when it is combined with Mitotane. Approved, Investigational Estazolam The serum concentration of Estazolam can be decreased when it is combined with Mitotane. Approved, Illicit Estradiol The serum concentration of Estradiol can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Estradiol acetate can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Estradiol benzoate The serum concentration of Estradiol benzoate can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Estradiol cypionate can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Estradiol dienanthate The serum concentration of Estradiol dienanthate can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Estradiol valerate can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Estramustine The serum concentration of Estramustine can be decreased when it is combined with Mitotane. Approved, Investigational Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Mitotane. Approved Estrone The serum concentration of Estrone can be decreased when it is combined with Mitotane. Approved Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Mitotane. Approved Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Mitotane. Approved, Investigational Ethanol The serum concentration of Ethanol can be decreased when it is combined with Mitotane. Approved Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitotane. Approved Ethosuximide The serum concentration of Ethosuximide can be decreased when it is combined with Mitotane. Approved Ethylmorphine The serum concentration of Ethylmorphine can be decreased when it is combined with Mitotane. Approved, Illicit Etizolam The serum concentration of Etizolam can be decreased when it is combined with Mitotane. Approved Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Mitotane. Approved, Investigational Etoposide The serum concentration of Etoposide can be decreased when it is combined with Mitotane. Approved Etoricoxib The serum concentration of Etoricoxib can be decreased when it is combined with Mitotane. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Mitotane. Approved Everolimus The serum concentration of Everolimus can be decreased when it is combined with Mitotane. Approved Exemestane The serum concentration of Exemestane can be decreased when it is combined with Mitotane. Approved, Investigational Famciclovir The serum concentration of Famciclovir can be decreased when it is combined with Mitotane. Approved, Investigational Felbamate The serum concentration of Felbamate can be decreased when it is combined with Mitotane. Approved Felodipine The serum concentration of Felodipine can be decreased when it is combined with Mitotane. Approved, Investigational Fenofibrate The serum concentration of Fenofibrate can be decreased when it is combined with Mitotane. Approved Fentanyl The serum concentration of Fentanyl can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of Fesoterodine can be decreased when it is combined with Mitotane. Approved Finasteride The serum concentration of Finasteride can be decreased when it is combined with Mitotane. Approved Fingolimod The serum concentration of Fingolimod can be decreased when it is combined with Mitotane. Approved, Investigational Flibanserin The serum concentration of Flibanserin can be decreased when it is combined with Mitotane. Approved, Investigational Fluasterone The serum concentration of Fluasterone can be decreased when it is combined with Mitotane. Investigational Fludrocortisone The serum concentration of Fludrocortisone can be decreased when it is combined with Mitotane. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be decreased when it is combined with Mitotane. Approved, Vet Approved Flunisolide The serum concentration of Flunisolide can be decreased when it is combined with Mitotane. Approved, Investigational Flunitrazepam The serum concentration of Flunitrazepam can be decreased when it is combined with Mitotane. Approved, Illicit Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be decreased when it is combined with Mitotane. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be decreased when it is combined with Mitotane. Approved, Withdrawn Fluorometholone The serum concentration of Fluorometholone can be decreased when it is combined with Mitotane. Approved, Investigational Fluoxetine The serum concentration of Fluoxetine can be decreased when it is combined with Mitotane. Approved, Vet Approved Fluprednidene The serum concentration of Fluprednidene can be decreased when it is combined with Mitotane. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be decreased when it is combined with Mitotane. Approved Flurandrenolide The serum concentration of Flurandrenolide can be decreased when it is combined with Mitotane. Approved Flurazepam The serum concentration of Flurazepam can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational Flutamide The serum concentration of Flutamide can be decreased when it is combined with Mitotane. Approved, Investigational Fluticasone furoate The serum concentration of Fluticasone furoate can be decreased when it is combined with Mitotane. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be decreased when it is combined with Mitotane. Approved Fluvastatin The serum concentration of Fluvastatin can be decreased when it is combined with Mitotane. Approved Formestane The serum concentration of Formestane can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Fosamprenavir The serum concentration of Fosamprenavir can be decreased when it is combined with Mitotane. Approved Fulvestrant The serum concentration of Fulvestrant can be decreased when it is combined with Mitotane. Approved, Investigational Galantamine The serum concentration of Galantamine can be decreased when it is combined with Mitotane. Approved Gefitinib The serum concentration of Gefitinib can be decreased when it is combined with Mitotane. Approved, Investigational Gemfibrozil The serum concentration of Gemfibrozil can be decreased when it is combined with Mitotane. Approved Gitoformate Gitoformate may decrease the cardiotoxic activities of Mitotane. Experimental Glipizide The serum concentration of Glipizide can be decreased when it is combined with Mitotane. Approved, Investigational Glyburide The serum concentration of Glyburide can be decreased when it is combined with Mitotane. Approved Granisetron The serum concentration of Granisetron can be decreased when it is combined with Mitotane. Approved, Investigational Grazoprevir The serum concentration of Grazoprevir can be decreased when it is combined with Mitotane. Approved Grepafloxacin The serum concentration of Grepafloxacin can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Guanfacine The serum concentration of Guanfacine can be decreased when it is combined with Mitotane. Approved, Investigational Halcinonide The serum concentration of Halcinonide can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Halofantrine The serum concentration of Halofantrine can be decreased when it is combined with Mitotane. Approved Haloperidol The serum concentration of Haloperidol can be decreased when it is combined with Mitotane. Approved Halothane The serum concentration of Halothane can be decreased when it is combined with Mitotane. Approved, Vet Approved HE3286 The serum concentration of HE3286 can be decreased when it is combined with Mitotane. Investigational Hexobarbital The serum concentration of Hexobarbital can be decreased when it is combined with Mitotane. Approved Histamine The serum concentration of Histamine can be decreased when it is combined with Mitotane. Approved, Investigational Hydrocodone The serum concentration of Hydrocodone can be decreased when it is combined with Mitotane. Approved, Illicit Hydrocortisone The serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane. Approved, Vet Approved Hydromorphone The serum concentration of Hydromorphone can be decreased when it is combined with Mitotane. Approved, Illicit Hydroxyprogesterone caproate The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Mitotane. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be decreased when it is combined with Mitotane. Approved Icotinib The serum concentration of Icotinib can be decreased when it is combined with Mitotane. Approved, Investigational Idelalisib The serum concentration of Idelalisib can be decreased when it is combined with Mitotane. Approved Ifosfamide The serum concentration of Ifosfamide can be decreased when it is combined with Mitotane. Approved Iloperidone The serum concentration of Iloperidone can be decreased when it is combined with Mitotane. Approved Imatinib The serum concentration of Imatinib can be decreased when it is combined with Mitotane. Approved Imidafenacin The serum concentration of Imidafenacin can be decreased when it is combined with Mitotane. Approved, Investigational Imipramine The serum concentration of Imipramine can be decreased when it is combined with Mitotane. Approved Imiquimod The serum concentration of Imiquimod can be decreased when it is combined with Mitotane. Approved, Investigational Indacaterol The serum concentration of Indacaterol can be decreased when it is combined with Mitotane. Approved Indapamide The serum concentration of Indapamide can be decreased when it is combined with Mitotane. Approved Indinavir The serum concentration of Indinavir can be decreased when it is combined with Mitotane. Approved Ipratropium bromide The serum concentration of Ipratropium bromide can be decreased when it is combined with Mitotane. Approved Irinotecan The serum concentration of Irinotecan can be decreased when it is combined with Mitotane. Approved, Investigational Isavuconazole The serum concentration of Isavuconazole can be decreased when it is combined with Mitotane. Approved, Investigational Isavuconazonium The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Mitotane resulting in a loss in efficacy. Approved, Investigational Isosorbide Dinitrate The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Mitotane. Approved, Investigational Isosorbide Mononitrate The serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Mitotane. Approved Isradipine The serum concentration of Isradipine can be decreased when it is combined with Mitotane. Approved, Investigational Istaroxime The serum concentration of Istaroxime can be decreased when it is combined with Mitotane. Investigational Itraconazole The serum concentration of Itraconazole can be decreased when it is combined with Mitotane. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be decreased when it is combined with Mitotane. Approved Ivacaftor The serum concentration of Ivacaftor can be decreased when it is combined with Mitotane. Approved Ivermectin The serum concentration of Ivermectin can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Ixabepilone The serum concentration of Ixabepilone can be decreased when it is combined with Mitotane. Approved, Investigational Ixazomib The serum concentration of Ixazomib can be decreased when it is combined with Mitotane. Approved, Investigational Ketamine The serum concentration of Ketamine can be decreased when it is combined with Mitotane. Approved, Vet Approved Ketazolam The serum concentration of Ketazolam can be decreased when it is combined with Mitotane. Approved Ketobemidone The serum concentration of Ketobemidone can be decreased when it is combined with Mitotane. Approved, Investigational Ketoconazole The serum concentration of Ketoconazole can be decreased when it is combined with Mitotane. Approved, Investigational Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Mitotane. Approved, Investigational Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Mitotane. Experimental Lansoprazole The serum concentration of Lansoprazole can be decreased when it is combined with Mitotane. Approved, Investigational Lapatinib The serum concentration of Lapatinib can be decreased when it is combined with Mitotane. Approved, Investigational Laquinimod The serum concentration of Laquinimod can be decreased when it is combined with Mitotane. Investigational Lenvatinib The serum concentration of Lenvatinib can be decreased when it is combined with Mitotane. Approved, Investigational Lercanidipine The serum concentration of Lercanidipine can be decreased when it is combined with Mitotane. Approved, Investigational Letermovir The serum concentration of Mitotane can be increased when it is combined with Letermovir. Approved, Investigational Letrozole The serum concentration of Letrozole can be decreased when it is combined with Mitotane. Approved, Investigational Levobupivacaine The serum concentration of Levobupivacaine can be decreased when it is combined with Mitotane. Approved, Investigational Levocetirizine The serum concentration of Levocetirizine can be decreased when it is combined with Mitotane. Approved Levomethadyl Acetate The serum concentration of Levomethadyl Acetate can be decreased when it is combined with Mitotane. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be decreased when it is combined with Mitotane. Approved, Investigational Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Mitotane. Approved, Investigational Levothyroxine The serum concentration of Levothyroxine can be decreased when it is combined with Mitotane. Approved Lidocaine The serum concentration of Lidocaine can be decreased when it is combined with Mitotane. Approved, Vet Approved Linagliptin The serum concentration of Linagliptin can be decreased when it is combined with Mitotane. Approved Lisuride The serum concentration of Lisuride can be decreased when it is combined with Mitotane. Approved, Investigational Lomitapide The serum concentration of Lomitapide can be decreased when it is combined with Mitotane. Approved, Investigational Loperamide The serum concentration of Loperamide can be decreased when it is combined with Mitotane. Approved Lopinavir The serum concentration of Lopinavir can be decreased when it is combined with Mitotane. Approved Loratadine The serum concentration of Loratadine can be decreased when it is combined with Mitotane. Approved, Investigational Lorcaserin The serum concentration of Lorcaserin can be decreased when it is combined with Mitotane. Approved Lorpiprazole The serum concentration of Lorpiprazole can be decreased when it is combined with Mitotane. Approved Losartan The serum concentration of Losartan can be decreased when it is combined with Mitotane. Approved Loteprednol The serum concentration of Loteprednol can be decreased when it is combined with Mitotane. Approved Lovastatin The serum concentration of Lovastatin can be decreased when it is combined with Mitotane. Approved, Investigational Lumefantrine The serum concentration of Lumefantrine can be decreased when it is combined with Mitotane. Approved Lurasidone The serum concentration of Lurasidone can be decreased when it is combined with Mitotane. Approved, Investigational Macimorelin The serum concentration of Macimorelin can be decreased when it is combined with Mitotane. Approved, Investigational Macitentan The serum concentration of Macitentan can be decreased when it is combined with Mitotane. Approved Maraviroc The serum concentration of Maraviroc can be decreased when it is combined with Mitotane. Approved, Investigational ME-609 The serum concentration of ME-609 can be decreased when it is combined with Mitotane. Investigational Mebendazole The serum concentration of Mebendazole can be decreased when it is combined with Mitotane. Approved, Vet Approved Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mitotane. Approved, Investigational Medrysone The serum concentration of Medrysone can be decreased when it is combined with Mitotane. Approved Mefloquine The serum concentration of Mefloquine can be decreased when it is combined with Mitotane. Approved, Investigational Melengestrol The serum concentration of Melengestrol can be decreased when it is combined with Mitotane. Vet Approved Meloxicam The serum concentration of Meloxicam can be decreased when it is combined with Mitotane. Approved, Vet Approved Methadone The serum concentration of Methadone can be decreased when it is combined with Mitotane. Approved Methaqualone The serum concentration of Methaqualone can be decreased when it is combined with Mitotane. Illicit, Withdrawn Methoxsalen The serum concentration of Methoxsalen can be decreased when it is combined with Mitotane. Approved Methoxyflurane The serum concentration of Methoxyflurane can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Methylprednisolone The serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane. Approved, Vet Approved Methyltestosterone The serum concentration of Methyltestosterone can be decreased when it is combined with Mitotane. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Mitotane. Experimental Metronidazole The serum concentration of Metronidazole can be decreased when it is combined with Mitotane. Approved Mexiletine The serum concentration of Mexiletine can be decreased when it is combined with Mitotane. Approved, Investigational Mianserin The serum concentration of Mianserin can be decreased when it is combined with Mitotane. Approved, Investigational Mibefradil The serum concentration of Mibefradil can be decreased when it is combined with Mitotane. Investigational, Withdrawn Miconazole The serum concentration of Miconazole can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Midazolam The serum concentration of Midazolam can be decreased when it is combined with Mitotane. Approved, Illicit Midostaurin The serum concentration of Midostaurin can be decreased when it is combined with Mitotane. Approved, Investigational Mifepristone The serum concentration of Mifepristone can be decreased when it is combined with Mitotane. Approved, Investigational Mirabegron The serum concentration of Mirabegron can be decreased when it is combined with Mitotane. Approved Mirtazapine The serum concentration of Mirtazapine can be decreased when it is combined with Mitotane. Approved Modafinil The serum concentration of Modafinil can be decreased when it is combined with Mitotane. Approved, Investigational Mometasone The serum concentration of Mometasone can be decreased when it is combined with Mitotane. Approved, Vet Approved Montelukast The serum concentration of Montelukast can be decreased when it is combined with Mitotane. Approved Morphine The serum concentration of Morphine can be decreased when it is combined with Mitotane. Approved, Investigational Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitotane. Approved, Investigational Naloxegol The serum concentration of Naloxegol can be decreased when it is combined with Mitotane. Approved Naloxone The serum concentration of Naloxone can be decreased when it is combined with Mitotane. Approved, Vet Approved Nateglinide The serum concentration of Nateglinide can be decreased when it is combined with Mitotane. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be decreased when it is combined with Mitotane. Investigational Nefazodone The serum concentration of Nefazodone can be decreased when it is combined with Mitotane. Approved, Withdrawn Nelfinavir The serum concentration of Nelfinavir can be decreased when it is combined with Mitotane. Approved Neratinib The serum concentration of Neratinib can be decreased when it is combined with Mitotane. Approved, Investigational Netupitant The serum concentration of Netupitant can be decreased when it is combined with Mitotane. Approved, Investigational Nevirapine The serum concentration of Nevirapine can be decreased when it is combined with Mitotane. Approved Nicardipine The serum concentration of Nicardipine can be decreased when it is combined with Mitotane. Approved, Investigational Nicotine The serum concentration of Nicotine can be decreased when it is combined with Mitotane. Approved Nifedipine The serum concentration of Nifedipine can be decreased when it is combined with Mitotane. Approved Nilotinib The serum concentration of Nilotinib can be decreased when it is combined with Mitotane. Approved, Investigational Nilvadipine The serum concentration of Nilvadipine can be decreased when it is combined with Mitotane. Approved, Investigational Nimodipine The serum concentration of Nimodipine can be decreased when it is combined with Mitotane. Approved, Investigational Nisoldipine The serum concentration of Nisoldipine can be decreased when it is combined with Mitotane. Approved Nitrazepam The serum concentration of Nitrazepam can be decreased when it is combined with Mitotane. Approved Nitrendipine The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane. Approved, Investigational Norethisterone The serum concentration of Norethisterone can be decreased when it is combined with Mitotane. Approved Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Mitotane. Approved Nortriptyline The serum concentration of Nortriptyline can be decreased when it is combined with Mitotane. Approved Odanacatib The serum concentration of Odanacatib can be decreased when it is combined with Mitotane. Investigational Olaparib The serum concentration of Olaparib can be decreased when it is combined with Mitotane. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Mitotane. Experimental, Investigational Oleoyl-estrone The serum concentration of Oleoyl-estrone can be decreased when it is combined with Mitotane. Investigational Olopatadine The serum concentration of Olopatadine can be decreased when it is combined with Mitotane. Approved Omeprazole The serum concentration of Omeprazole can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Ondansetron The serum concentration of Ondansetron can be decreased when it is combined with Mitotane. Approved Opium The serum concentration of Opium can be decreased when it is combined with Mitotane. Approved, Illicit Orphenadrine The serum concentration of Orphenadrine can be decreased when it is combined with Mitotane. Approved Osimertinib The serum concentration of Osimertinib can be decreased when it is combined with Mitotane. Approved Ospemifene The serum concentration of Ospemifene can be decreased when it is combined with Mitotane. Approved, Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Mitotane. Approved Oxazepam The serum concentration of Oxazepam can be decreased when it is combined with Mitotane. Approved Oxybutynin The serum concentration of Oxybutynin can be decreased when it is combined with Mitotane. Approved, Investigational Oxycodone The serum concentration of Oxycodone can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational Oxymorphone The serum concentration of Oxymorphone can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Paclitaxel The serum concentration of Paclitaxel can be decreased when it is combined with Mitotane. Approved, Vet Approved Palbociclib The serum concentration of Palbociclib can be decreased when it is combined with Mitotane. Approved, Investigational Palonosetron The serum concentration of Palonosetron can be decreased when it is combined with Mitotane. Approved, Investigational Panobinostat The serum concentration of Panobinostat can be decreased when it is combined with Mitotane. Approved, Investigational Pantoprazole The serum concentration of Pantoprazole can be decreased when it is combined with Mitotane. Approved Paramethadione The serum concentration of Paramethadione can be decreased when it is combined with Mitotane. Approved Paramethasone The serum concentration of Paramethasone can be decreased when it is combined with Mitotane. Approved Parecoxib The serum concentration of Parecoxib can be decreased when it is combined with Mitotane. Approved Paricalcitol The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. Approved, Investigational Paritaprevir The serum concentration of Paritaprevir can be decreased when it is combined with Mitotane. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be decreased when it is combined with Mitotane. Approved Pentamidine The serum concentration of Pentamidine can be decreased when it is combined with Mitotane. Approved, Investigational Perampanel The serum concentration of Perampanel can be decreased when it is combined with Mitotane. Approved Pergolide The serum concentration of Pergolide can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved, Withdrawn Perhexiline The serum concentration of Perhexiline can be decreased when it is combined with Mitotane. Approved, Investigational Permethrin The serum concentration of Permethrin can be decreased when it is combined with Mitotane. Approved, Investigational Perospirone The serum concentration of Perospirone can be decreased when it is combined with Mitotane. Approved Perphenazine The serum concentration of Perphenazine can be decreased when it is combined with Mitotane. Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Mitotane. Experimental Pethidine The serum concentration of Pethidine can be decreased when it is combined with Mitotane. Approved Phenacetin The serum concentration of Phenacetin can be decreased when it is combined with Mitotane. Withdrawn Phenoxybenzamine The serum concentration of Phenoxybenzamine can be decreased when it is combined with Mitotane. Approved Phenprocoumon The serum concentration of Phenprocoumon can be decreased when it is combined with Mitotane. Approved, Investigational Phenytoin The serum concentration of Phenytoin can be decreased when it is combined with Mitotane. Approved, Vet Approved Pilocarpine The serum concentration of Pilocarpine can be decreased when it is combined with Mitotane. Approved, Investigational Pimecrolimus The serum concentration of Pimecrolimus can be decreased when it is combined with Mitotane. Approved, Investigational Pimozide The serum concentration of Pimozide can be decreased when it is combined with Mitotane. Approved Pinacidil The serum concentration of Pinacidil can be decreased when it is combined with Mitotane. Approved Pioglitazone The serum concentration of Pioglitazone can be decreased when it is combined with Mitotane. Approved, Investigational Piperaquine The serum concentration of Piperaquine can be decreased when it is combined with Mitotane. Approved, Investigational Pipotiazine The serum concentration of Pipotiazine can be decreased when it is combined with Mitotane. Approved, Investigational Pitolisant The serum concentration of Pitolisant can be decreased when it is combined with Mitotane. Approved, Investigational Podofilox The serum concentration of Podofilox can be decreased when it is combined with Mitotane. Approved Pomalidomide The serum concentration of Pomalidomide can be decreased when it is combined with Mitotane. Approved Ponatinib The serum concentration of Ponatinib can be decreased when it is combined with Mitotane. Approved, Investigational Posaconazole The serum concentration of Posaconazole can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Prasterone The serum concentration of Prasterone can be decreased when it is combined with Mitotane. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be decreased when it is combined with Mitotane. Investigational Prasugrel The serum concentration of Prasugrel can be decreased when it is combined with Mitotane. Approved Pravastatin The serum concentration of Pravastatin can be decreased when it is combined with Mitotane. Approved Prazepam The serum concentration of Prazepam can be decreased when it is combined with Mitotane. Approved, Illicit Praziquantel The serum concentration of Praziquantel can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Prednicarbate The serum concentration of Prednicarbate can be decreased when it is combined with Mitotane. Approved, Investigational Prednisolone The serum concentration of Prednisolone can be decreased when it is combined with Mitotane. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be decreased when it is combined with Mitotane. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be decreased when it is combined with Mitotane. Approved, Experimental, Investigational Primaquine The serum concentration of Primaquine can be decreased when it is combined with Mitotane. Approved Prochlorperazine The serum concentration of Prochlorperazine can be decreased when it is combined with Mitotane. Approved, Vet Approved Progesterone The serum concentration of Progesterone can be decreased when it is combined with Mitotane. Approved, Vet Approved Proguanil The serum concentration of Proguanil can be decreased when it is combined with Mitotane. Approved Promazine The serum concentration of Promazine can be decreased when it is combined with Mitotane. Approved, Vet Approved Propafenone The serum concentration of Propafenone can be decreased when it is combined with Mitotane. Approved Propofol The serum concentration of Propofol can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Propoxyphene napsylate The serum concentration of Propoxyphene napsylate can be decreased when it is combined with Mitotane. Approved Propranolol The serum concentration of Propranolol can be decreased when it is combined with Mitotane. Approved, Investigational Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Mitotane. Experimental Pyrazinamide The serum concentration of Pyrazinamide can be decreased when it is combined with Mitotane. Approved, Investigational Quazepam The serum concentration of Quazepam can be decreased when it is combined with Mitotane. Approved, Illicit Quetiapine The serum concentration of Quetiapine can be decreased when it is combined with Mitotane. Approved Quinacrine The serum concentration of Quinacrine can be decreased when it is combined with Mitotane. Approved, Investigational Quinidine The serum concentration of Quinidine can be decreased when it is combined with Mitotane. Approved, Investigational Quinine The serum concentration of Quinine can be decreased when it is combined with Mitotane. Approved Rabeprazole The serum concentration of Rabeprazole can be decreased when it is combined with Mitotane. Approved, Investigational Raloxifene The serum concentration of Raloxifene can be decreased when it is combined with Mitotane. Approved, Investigational Ramelteon The serum concentration of Ramelteon can be decreased when it is combined with Mitotane. Approved, Investigational Ranolazine The serum concentration of Ranolazine can be decreased when it is combined with Mitotane. Approved, Investigational Reboxetine The serum concentration of Reboxetine can be decreased when it is combined with Mitotane. Approved, Investigational Regorafenib The serum concentration of Regorafenib can be decreased when it is combined with Mitotane. Approved Repaglinide The serum concentration of Repaglinide can be decreased when it is combined with Mitotane. Approved, Investigational Retapamulin The serum concentration of Retapamulin can be decreased when it is combined with Mitotane. Approved Ribociclib The serum concentration of Ribociclib can be decreased when it is combined with Mitotane. Approved, Investigational Rifabutin The serum concentration of Rifabutin can be decreased when it is combined with Mitotane. Approved, Investigational Rifampicin The serum concentration of Rifampicin can be decreased when it is combined with Mitotane. Approved Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Mitotane. Approved Rimexolone The serum concentration of Rimexolone can be decreased when it is combined with Mitotane. Approved Rimonabant The serum concentration of Rimonabant can be decreased when it is combined with Mitotane. Approved, Investigational Riociguat The serum concentration of Riociguat can be decreased when it is combined with Mitotane. Approved Risperidone The serum concentration of Risperidone can be decreased when it is combined with Mitotane. Approved, Investigational Ritonavir The serum concentration of Ritonavir can be decreased when it is combined with Mitotane. Approved, Investigational Rivaroxaban The serum concentration of Rivaroxaban can be decreased when it is combined with Mitotane. Approved Rofecoxib The serum concentration of Rofecoxib can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Roflumilast The serum concentration of Roflumilast can be decreased when it is combined with Mitotane. Approved Rolapitant The serum concentration of Rolapitant can be decreased when it is combined with Mitotane. Approved, Investigational Romidepsin The serum concentration of Romidepsin can be decreased when it is combined with Mitotane. Approved, Investigational Ropinirole The serum concentration of Ropinirole can be decreased when it is combined with Mitotane. Approved, Investigational Ropivacaine The serum concentration of Ropivacaine can be decreased when it is combined with Mitotane. Approved Rosuvastatin The serum concentration of Rosuvastatin can be decreased when it is combined with Mitotane. Approved Rotigotine The serum concentration of Rotigotine can be decreased when it is combined with Mitotane. Approved Roxithromycin The serum concentration of Roxithromycin can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Rucaparib The serum concentration of Rucaparib can be decreased when it is combined with Mitotane. Approved, Investigational Rupatadine The serum concentration of Rupatadine can be decreased when it is combined with Mitotane. Approved Ruxolitinib The serum concentration of Ruxolitinib can be decreased when it is combined with Mitotane. Approved Safinamide The serum concentration of Safinamide can be decreased when it is combined with Mitotane. Approved, Investigational Salmeterol The serum concentration of Salmeterol can be decreased when it is combined with Mitotane. Approved Saquinavir The serum concentration of Saquinavir can be decreased when it is combined with Mitotane. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be decreased when it is combined with Mitotane. Approved Selegiline The serum concentration of Selegiline can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Selexipag The serum concentration of Selexipag can be decreased when it is combined with Mitotane. Approved Seratrodast The serum concentration of Seratrodast can be decreased when it is combined with Mitotane. Approved Sertindole The serum concentration of Sertindole can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Sertraline The serum concentration of Sertraline can be decreased when it is combined with Mitotane. Approved Sevoflurane The serum concentration of Sevoflurane can be decreased when it is combined with Mitotane. Approved, Vet Approved Sibutramine The serum concentration of Sibutramine can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational, Withdrawn Sildenafil The serum concentration of Sildenafil can be decreased when it is combined with Mitotane. Approved, Investigational Silodosin The serum concentration of Silodosin can be decreased when it is combined with Mitotane. Approved Simeprevir The serum concentration of Simeprevir can be decreased when it is combined with Mitotane. Approved Simvastatin The serum concentration of Simvastatin can be decreased when it is combined with Mitotane. Approved Sirolimus The serum concentration of Sirolimus can be decreased when it is combined with Mitotane. Approved, Investigational Sitagliptin The serum concentration of Sitagliptin can be decreased when it is combined with Mitotane. Approved, Investigational Solifenacin The serum concentration of Solifenacin can be decreased when it is combined with Mitotane. Approved Sonidegib The serum concentration of Sonidegib can be decreased when it is combined with Mitotane. Approved, Investigational Sorafenib The serum concentration of Sorafenib can be decreased when it is combined with Mitotane. Approved, Investigational Spiramycin The serum concentration of Spiramycin can be decreased when it is combined with Mitotane. Approved Spironolactone The therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone. Approved Sufentanil The serum concentration of Sufentanil can be decreased when it is combined with Mitotane. Approved, Investigational Sulfadiazine The serum concentration of Sulfadiazine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Sulfamethoxazole The serum concentration of Sulfamethoxazole can be decreased when it is combined with Mitotane. Approved Sulfinpyrazone The serum concentration of Sulfinpyrazone can be decreased when it is combined with Mitotane. Approved Sunitinib The serum concentration of Sunitinib can be decreased when it is combined with Mitotane. Approved, Investigational Suvorexant The serum concentration of Suvorexant can be decreased when it is combined with Mitotane. Approved, Investigational Synthetic Conjugated Estrogens, A The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Mitotane. Approved Synthetic Conjugated Estrogens, B The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Mitotane. Approved Tacrolimus The serum concentration of Tacrolimus can be decreased when it is combined with Mitotane. Approved, Investigational Tadalafil The serum concentration of Tadalafil can be decreased when it is combined with Mitotane. Approved, Investigational Tamoxifen The serum concentration of Tamoxifen can be decreased when it is combined with Mitotane. Approved Tamsulosin The serum concentration of Tamsulosin can be decreased when it is combined with Mitotane. Approved, Investigational Tasimelteon The serum concentration of Tasimelteon can be decreased when it is combined with Mitotane. Approved, Investigational Tasosartan The serum concentration of Tasosartan can be decreased when it is combined with Mitotane. Approved Taurochenodeoxycholic acid The serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Mitotane. Experimental Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Mitotane. Approved, Withdrawn Telithromycin The serum concentration of Telithromycin can be decreased when it is combined with Mitotane. Approved Temazepam The serum concentration of Temazepam can be decreased when it is combined with Mitotane. Approved, Investigational Temsirolimus The serum concentration of Temsirolimus can be decreased when it is combined with Mitotane. Approved Teniposide The serum concentration of Teniposide can be decreased when it is combined with Mitotane. Approved Terbinafine The serum concentration of Terbinafine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Terfenadine The serum concentration of Terfenadine can be decreased when it is combined with Mitotane. Approved, Withdrawn Tesmilifene The serum concentration of Tesmilifene can be decreased when it is combined with Mitotane. Investigational Testosterone The serum concentration of Testosterone can be decreased when it is combined with Mitotane. Approved, Investigational Testosterone cypionate The serum concentration of Testosterone cypionate can be decreased when it is combined with Mitotane. Approved Testosterone enanthate The serum concentration of Testosterone enanthate can be decreased when it is combined with Mitotane. Approved Testosterone propionate The serum concentration of Testosterone propionate can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The serum concentration of Testosterone undecanoate can be decreased when it is combined with Mitotane. Approved, Investigational Tetracycline The serum concentration of Tetracycline can be decreased when it is combined with Mitotane. Approved, Vet Approved Tezacaftor The serum concentration of Tezacaftor can be decreased when it is combined with Mitotane. Approved, Investigational Theophylline The serum concentration of Theophylline can be decreased when it is combined with Mitotane. Approved Thiotepa The serum concentration of Thiotepa can be decreased when it is combined with Mitotane. Approved, Investigational Tiagabine The serum concentration of Tiagabine can be decreased when it is combined with Mitotane. Approved, Investigational Ticagrelor The serum concentration of Ticagrelor can be decreased when it is combined with Mitotane. Approved Ticlopidine The serum concentration of Ticlopidine can be decreased when it is combined with Mitotane. Approved Tinidazole The serum concentration of Tinidazole can be decreased when it is combined with Mitotane. Approved, Investigational Tiotropium The serum concentration of Tiotropium can be decreased when it is combined with Mitotane. Approved Tipranavir The serum concentration of Tipranavir can be decreased when it is combined with Mitotane. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be decreased when it is combined with Mitotane. Approved, Withdrawn Tocopherol The serum concentration of Tocopherol can be decreased when it is combined with Mitotane. Approved, Investigational Tofacitinib The serum concentration of Tofacitinib can be decreased when it is combined with Mitotane. Approved, Investigational Tolterodine The serum concentration of Tolterodine can be decreased when it is combined with Mitotane. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be decreased when it is combined with Mitotane. Approved Toremifene The serum concentration of Toremifene can be decreased when it is combined with Mitotane. Approved, Investigational Trabectedin The serum concentration of Trabectedin can be decreased when it is combined with Mitotane. Approved, Investigational Tramadol The serum concentration of Tramadol can be decreased when it is combined with Mitotane. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Mitotane. Approved, Investigational Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Mitotane. Approved, Investigational Trazodone The serum concentration of Trazodone can be decreased when it is combined with Mitotane. Approved, Investigational Tretinoin The serum concentration of Tretinoin can be decreased when it is combined with Mitotane. Approved, Investigational, Nutraceutical Triamcinolone The serum concentration of Triamcinolone can be decreased when it is combined with Mitotane. Approved, Vet Approved Triazolam The serum concentration of Triazolam can be decreased when it is combined with Mitotane. Approved, Investigational Trimethadione The serum concentration of Trimethadione can be decreased when it is combined with Mitotane. Approved Trimethoprim The serum concentration of Trimethoprim can be decreased when it is combined with Mitotane. Approved, Vet Approved Trimipramine The serum concentration of Trimipramine can be decreased when it is combined with Mitotane. Approved Troglitazone The serum concentration of Troglitazone can be decreased when it is combined with Mitotane. Investigational, Withdrawn Troleandomycin The serum concentration of Troleandomycin can be decreased when it is combined with Mitotane. Approved Udenafil The serum concentration of Udenafil can be decreased when it is combined with Mitotane. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Mitotane. Approved Ulobetasol The serum concentration of Ulobetasol can be decreased when it is combined with Mitotane. Approved Valbenazine The serum concentration of Valbenazine can be decreased when it is combined with Mitotane. Approved, Investigational Valdecoxib The serum concentration of Valdecoxib can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Vandetanib The serum concentration of Vandetanib can be decreased when it is combined with Mitotane. Approved Vanoxerine The serum concentration of Vanoxerine can be decreased when it is combined with Mitotane. Investigational Vardenafil The serum concentration of Vardenafil can be decreased when it is combined with Mitotane. Approved Velpatasvir The serum concentration of Velpatasvir can be decreased when it is combined with Mitotane. Approved, Investigational Vemurafenib The serum concentration of Vemurafenib can be decreased when it is combined with Mitotane. Approved Venetoclax The serum concentration of Venetoclax can be decreased when it is combined with Mitotane. Approved, Investigational Venlafaxine The serum concentration of Venlafaxine can be decreased when it is combined with Mitotane. Approved Verapamil The serum concentration of Verapamil can be decreased when it is combined with Mitotane. Approved Vicriviroc The serum concentration of Vicriviroc can be decreased when it is combined with Mitotane. Investigational Vilanterol The serum concentration of Vilanterol can be decreased when it is combined with Mitotane. Approved Vilazodone The serum concentration of Vilazodone can be decreased when it is combined with Mitotane. Approved Vinblastine The serum concentration of Vinblastine can be decreased when it is combined with Mitotane. Approved Vincristine The serum concentration of Vincristine can be decreased when it is combined with Mitotane. Approved, Investigational Vindesine The serum concentration of Vindesine can be decreased when it is combined with Mitotane. Approved, Investigational Vinorelbine The serum concentration of Vinorelbine can be decreased when it is combined with Mitotane. Approved, Investigational Vismodegib The serum concentration of Vismodegib can be decreased when it is combined with Mitotane. Approved, Investigational Vorapaxar The serum concentration of Vorapaxar can be decreased when it is combined with Mitotane. Approved Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Mitotane. Approved, Investigational Vortioxetine The serum concentration of Vortioxetine can be decreased when it is combined with Mitotane. Approved, Investigational Voxilaprevir The serum concentration of Voxilaprevir can be decreased when it is combined with Mitotane. Approved, Investigational Warfarin The serum concentration of Warfarin can be decreased when it is combined with Mitotane. Approved Yohimbine The serum concentration of Yohimbine can be decreased when it is combined with Mitotane. Approved, Investigational, Vet Approved Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Mitotane. Approved, Investigational Zalcitabine The serum concentration of Zalcitabine can be decreased when it is combined with Mitotane. Approved, Investigational Zaleplon The serum concentration of Zaleplon can be decreased when it is combined with Mitotane. Approved, Illicit, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Mitotane. Approved Zileuton The serum concentration of Zileuton can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Ziprasidone The serum concentration of Ziprasidone can be decreased when it is combined with Mitotane. Approved Zolpidem The serum concentration of Zolpidem can be decreased when it is combined with Mitotane. Approved Zomepirac The serum concentration of Zomepirac can be decreased when it is combined with Mitotane. Withdrawn Zonisamide The serum concentration of Zonisamide can be decreased when it is combined with Mitotane. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be decreased when it is combined with Mitotane. Approved Zotepine The serum concentration of Zotepine can be decreased when it is combined with Mitotane. Approved, Investigational, Withdrawn Zuclopenthixol The serum concentration of Zuclopenthixol can be decreased when it is combined with Mitotane. Approved, Investigational - Food Interactions
- Take without regard to meals.
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014786
- KEGG Drug
- D00420
- PubChem Compound
- 4211
- PubChem Substance
- 46508319
- ChemSpider
- 4066
- ChEBI
- 6954
- ChEMBL
- CHEMBL1670
- Therapeutic Targets Database
- DAP000033
- PharmGKB
- PA164746157
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Mitotane
- ATC Codes
- L01XX23 — Mitotane
- AHFS Codes
- 10:00.00 — Antineoplastic Agents
- MSDS
- Download (57 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Prostate Cancer 1 2 Terminated Treatment Recurrent Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma 1 3 Active Not Recruiting Treatment Stage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma 1 3 Completed Treatment Carcinoma, Adrenal Cortical 1 3 Unknown Status Treatment Adrenocortical Carcinoma 1
Pharmacoeconomics
- Manufacturers
- Bristol myers squibb
- Packagers
- B&B Pharmaceuticals
- Bristol-Myers Squibb Co.
- Mead Johnson and Co.
- Dosage forms
Form Route Strength Tablet Oral 500 mg Tablet Oral 500 mg/1 - Prices
Unit description Cost Unit Mitotane powder 7.75USD g Lysodren 500 mg tablet 5.13USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 77 °C PhysProp water solubility 0.1 mg/L (at 25 °C) BIGGAR,JW & RIGGS,RI (1974) logP 6 Not Available logS -6.51 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 9.42e-06 mg/mL ALOGPS logP 6.08 ALOGPS logP 6.11 ChemAxon logS -7.5 ALOGPS Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 0 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 79.97 m3·mol-1 ChemAxon Polarizability 29.93 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9942 Blood Brain Barrier + 0.9905 Caco-2 permeable + 0.8815 P-glycoprotein substrate Non-substrate 0.8053 P-glycoprotein inhibitor I Non-inhibitor 0.9004 P-glycoprotein inhibitor II Non-inhibitor 0.988 Renal organic cation transporter Non-inhibitor 0.7959 CYP450 2C9 substrate Non-substrate 0.7899 CYP450 2D6 substrate Non-substrate 0.818 CYP450 3A4 substrate Non-substrate 0.7045 CYP450 1A2 substrate Inhibitor 0.9542 CYP450 2C9 inhibitor Inhibitor 0.7241 CYP450 2D6 inhibitor Non-inhibitor 0.9349 CYP450 2C19 inhibitor Inhibitor 0.8993 CYP450 3A4 inhibitor Non-inhibitor 0.8629 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8 Ames test Non AMES toxic 0.9751 Carcinogenicity Non-carcinogens 0.575 Biodegradation Not ready biodegradable 0.9596 Rat acute toxicity 2.1911 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9221 hERG inhibition (predictor II) Non-inhibitor 0.875
Spectra
- Mass Spec (NIST)
- Download (8.84 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - GC-EI-Q GC-MS splash10-000i-2590000000-2d3f8090ffa4733bf9ee Mass Spectrum (Electron Ionization) MS splash10-000i-2690000000-770065ddc57899130a31 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available 1H NMR Spectrum 1D NMR Not Applicable 13C NMR Spectrum 1D NMR Not Applicable
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Chlorobenzenes / Aryl chlorides / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides
- Substituents
- Diphenylmethane / Halobenzene / Chlorobenzene / Aryl halide / Aryl chloride / Hydrocarbon derivative / Organochloride / Organohalogen compound / Alkyl halide / Alkyl chloride
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inducer
- General Function
- Steroid 11-beta-monooxygenase activity
- Specific Function
- Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
- Gene Name
- CYP11B1
- Uniprot ID
- P15538
- Uniprot Name
- Cytochrome P450 11B1, mitochondrial
- Molecular Weight
- 57572.44 Da
References
- Lindhe O, Skogseid B, Brandt I: Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. J Clin Endocrinol Metab. 2002 Mar;87(3):1319-26. [PubMed:11889204]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Unknown
- General Function
- Iron ion binding
- Specific Function
- Participates in the synthesis of thyroid hormones. Essential for the synthesis of various steroid hormones, participates in the reduction of mitochondrial cytochrome P450 for steroidogenesis. Trans...
- Gene Name
- FDX1
- Uniprot ID
- P10109
- Uniprot Name
- Adrenodoxin, mitochondrial
- Molecular Weight
- 19392.475 Da
References
- Kandul SV, Iatsyk MI, Kononenko VIa: [Comparative study of the effect of chloditan on the concentration of cytochrome P-450 and adrenodoxin in various organs of the dog and rat]. Fiziol Zh. 1986 Sep-Oct;32(5):579-84. [PubMed:3770229]
- Cabrini DA, Campos MM, Tratsk KS, Merino VF, Silva JA Jr, Souza GE, Avellar MC, Pesquero JB, Calixto JB: Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats. Br J Pharmacol. 2001 Jan;132(2):567-77. [PubMed:11159707]
- Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD, Wotring LL: Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother Pharmacol. 1997;39(6):537-40. [PubMed:9118466]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Scippo ML, Argiris C, Van De Weerdt C, Muller M, Willemsen P, Martial J, Maghuin-Rogister G: Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem. 2004 Feb;378(3):664-9. Epub 2003 Oct 25. [PubMed:14579009]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
- Gene Name
- PGR
- Uniprot ID
- P06401
- Uniprot Name
- Progesterone receptor
- Molecular Weight
- 98979.96 Da
References
- Scippo ML, Argiris C, Van De Weerdt C, Muller M, Willemsen P, Martial J, Maghuin-Rogister G: Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem. 2004 Feb;378(3):664-9. Epub 2003 Oct 25. [PubMed:14579009]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Maness SC, McDonnell DP, Gaido KW: Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. Toxicol Appl Pharmacol. 1998 Jul;151(1):135-42. [PubMed:9705896]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Androgen binding
- Specific Function
- Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
- Gene Name
- SHBG
- Uniprot ID
- P04278
- Uniprot Name
- Sex hormone-binding globulin
- Molecular Weight
- 43778.755 Da
References
- Nader N, Raverot G, Emptoz-Bonneton A, Dechaud H, Bonnay M, Baudin E, Pugeat M: Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab. 2006 Jun;91(6):2165-70. Epub 2006 Mar 21. [PubMed:16551731]
- van Seters AP, Moolenaar AJ: Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh). 1991 May;124(5):526-33. [PubMed:1903011]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Steroid binding
- Specific Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Nader N, Raverot G, Emptoz-Bonneton A, Dechaud H, Bonnay M, Baudin E, Pugeat M: Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab. 2006 Jun;91(6):2165-70. Epub 2006 Mar 21. [PubMed:16551731]
- Tron'ko MD: [Effect of chlodithane (o,p'-DDD) on transcortin binding ability in Itsenko-Cushing's disease]. Fiziol Zh. 1970 Nov-Dec;16(6):844-5. [PubMed:5520073]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 00:59